# Compare the Four Peptides — Peptide Download

> A plain-English side-by-side comparison of BPC-157, Ipamorelin, Semaglutide, and GHK-Cu — mechanism class, evidence maturity, regulatory status, and what each is actually studied for.

BPC-157, Ipamorelin, Semaglutide, and GHK-Cu from the same angle — what each is studied for, how strong the evidence is, and where it currently stands with regulators.

## The short version

The four compounds on this desk were chosen because they sit at four distinct points on two important axes: the axis from 'very thin evidence' to 'large replicated human trials,' and the axis from 'unapproved research compound' to 'approved prescription medicine.' Putting them on the same table makes those differences concrete rather than abstract.

Semaglutide is in a different league of clinical evidence from the others. BPC-157 and Ipamorelin are at the preclinical-to-early-human stage. GHK-Cu sits between them — well-established as a cosmetic ingredient but clinically uncharacterized as a systemic or injectable compound. Keeping those distinctions in view is the whole point of a comparison page.

## Side-by-side comparison

| | **BPC-157** | **Ipamorelin** | **Semaglutide** | **GHK-Cu** |
|---|---|---|---|---|
| **Full name** | Body Protection Compound 157 | Ipamorelin | Semaglutide | Glycyl-L-Histidyl-L-Lysine Copper(II) complex |
| **Peptide length** | 15 amino acids | 5 amino acids (pentapeptide) | 31 amino acids (acylated) | 3 amino acids (tripeptide) + Cu(II) |
| **Molecule class** | Cytoprotective / regenerative research peptide | Selective GH secretagogue (GHS-R1a agonist) | GLP-1 receptor agonist (incretin mimetic) | Copper-binding peptide (cosmetic / research) |
| **Primary mechanism** | Angiogenesis via VEGFR2-Akt-eNOS; FAK-paxillin cell migration [4] | GH pulse from pituitary GHS-R1a activation; no ACTH/cortisol rise [11] | Glucose-dependent insulin secretion; appetite suppression via hypothalamic GLP-1R [16] | Fibroblast collagen/elastin synthesis; lysyl oxidase cross-linking; broad gene-expression modulation [19, 21] |
| **What it is mainly studied for** | Tissue repair (tendon, gut, muscle, nerve) in animal models [2] | GH release; gastric motility (failed Phase 2); weight loss in preclinical models [8, 6] | Type 2 diabetes; chronic weight management; cardiovascular risk; kidney disease [14, 15, 16] | Skin collagen production; anti-wrinkle; hair growth (topical human trials) [18, 20, 21] |
| **Evidence maturity** | Extensive animal (rodent) data; only ~3 small human pilots; no large RCT [1, 2] | Human PK data (n=8) [9]; one Phase 2 RCT missed endpoint (n=114) [8]; otherwise preclinical | Large, independent Phase 3 RCTs (thousands of participants); multiple approved indications [13, 14, 15, 16] | Small human topical trials (n=13–45); large cell/gene-expression database evidence [18, 19, 20, 21] |
| **Regulatory status** | Not approved anywhere; not eligible for 503A pharmacy compounding (FDA 2023) | Never approved; removed from 503A Category 2 list (FDA 2024); WADA S2 prohibited | FDA-approved (multiple indications; subcutaneous and oral) | Topical Copper Tripeptide-1: legal cosmetic ingredient (US/EU/UK); injectable/systemic: unapproved |
| **WADA status** | Prohibited (S0: non-approved substance) | Prohibited (S2: GH secretagogues) | Not currently prohibited | Not currently listed (verify current list) |
| **Human dosing data** | None validated in humans | PK only (IV, healthy volunteers; 1999) [9] | Extensive (approved labelling, STEP/SELECT/FLOW trials) | None for injectable; topical concentrations studied in trials |
| **Primary safety concerns** | Thin evidence base; single-lab replication gap; VEGFR2 pro-angiogenic mechanism; unregulated supply [2] | Class-level cardiovascular signal (related GHS agonist, rat, 28 days) [7]; GH axis / IGF-1 / cancer concern; long-term human data absent | GI intolerance (leading cause of discontinuation); gallbladder disease; lean-mass loss; weight regain after stopping [17] | Irritation at high strength; vitamin C / acid incompatibility; injectable use unstudied; limited large-trial evidence [18] |

*Note: all findings attributed to species/model in the compound pages. This table summarizes; the individual compound pages carry the primary citations and caveats.*

## Reading the evidence spectrum

The comparison table above makes visible something that is easy to lose in peptide discussions: the enormous range of how well-studied these compounds are in humans.

At one end, **semaglutide** has been tested in trials totaling more than 20,000 human participants across multiple disease categories, by multiple independent research groups, with public pre-registration and peer review. The evidence is mature, replicated, and settled in terms of what the drug does at approved doses. The safety concerns are real but characterized.

At the other end, **BPC-157** has three tiny human pilot studies to its name and a literature dominated by a single research group's rodent work [2]. The gap between the enthusiasm in wellness communities and the depth of the human evidence is perhaps the widest of any compound on this desk.

**Ipamorelin** is somewhere in the middle — it has actual human pharmacokinetic data and a completed Phase 2 trial, which is more than most research peptides. The trial missed its endpoint [8], but the act of running a controlled trial puts it ahead of purely preclinical compounds.

**GHK-Cu** occupies a different axis: it has legitimate human evidence but only in one context (small topical skin trials). The gap between what in-vitro gene-expression data suggest and what has been confirmed in large, controlled human trials is the key caveat for this compound.

Knowing where a compound sits on the evidence spectrum is not the same as knowing whether it will matter to you. But it is the information you need to form honest expectations.

---

A calibrated literature digest — curious about the evidence, disciplined about what the evidence actually says.